According to a release issued by Ranbaxy Laboratories to the BSE today, Glimepiride tablets are prescribed as an adjunct to diet and exercise to lower blood glucose in patients with non-insulin-dependent (Type II) diabetes mellitus (NIDDM).
"The Office of Generic Drugs, US Food and Drug Administration, has determined the company's formulations to be bio-equivalent and have the same therapeutic effect as that of the reference listed drug Amaryl tablets, a registered trademark of Aventis Pharmaceuticals Inc," the release added.
